• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Company Encyclopedia
View More
name
JCR Pharmaceuticals Co., Ltd.
4552.JP
Shareholder
Ownership%OwnedShare ChgReport Date
No Data
News
View More

JCR Pharmaceuticals Announces Licensing Agreement With Menagen To Commercialize Agalsidase Beta BS I.V. Infusion

Oct 1 (Reuters) - JCR Pharmaceuticals Co Ltd (4552.T) :* JCR PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH MENAGEN TO COMMERCIALIZE AGALSIDASE BETA BS I.V. INFUSION (JCR) ACROSS NINE MENAT MARKETS* JCR PHARMACEUTICALS CO LTD: DOES NOT EXPECT A MATERIAL IMPACT ON FY2025 CONSOLIDATED RESULTS FROM MENAGEN DEAL Source text: Further company coverage: (4552.T)(((( Reuters.Briefs@thomsonreuters.com ;));))

Reuters·10/02/2025 01:37
JP
4552
0.00%
Reuters·10/02/2025 01:37
JP
4552
0.00%
© 2025 Longbridge|Disclaimer